The novel combination of nitroxoline and PD-1 blockade, exerts a potent antitumor effect in a mouse model of prostate cancer

摘要: Programmed cell death protein 1 (PD-1) blockade is a promising therapeutic strategy against prostate cancer. Nitroxoline has been found to have effective anticancer properties in several cancer types. We investigated the efficacy of combination therapy involving nitroxoline and PD-1 mouse model. In our vitro analysis, we that inhibited viability proliferation line RM9-Luc-PSA. Additionally, downregulated expressions phospho-PI3 kinase, phospho-Akt (Thr308), (Ser473), phospho-GSK-3β, Bcl-2, Bcl-xL. also programmed death-ligand (PD-L1) expression levels tumor tissue. murine orthotopic model, plus synergistically suppressed growth when compared with or alone, leading reductions weight, bioluminescence signals, serum prostate-specific antigen levels. Furthermore, fluorescence-activated sorting analysis showed significantly enhanced antitumor immunity by increasing CD44+CD62L+CD8+ memory T numbers reducing myeloid-derived suppressor peripheral blood. conclusion, findings suggest may be treatment patients